Rosen Law Firm Files Securities Class Action Lawsuit Against ImmunityBio

Lawsuit alleges ImmunityBio made false and misleading statements about its drug Anktiva

Mar. 27, 2026 at 2:36am

Got story updates? Submit your updates here. ›

The Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026. The lawsuit alleges that ImmunityBio and its executives made false and misleading statements about the capabilities of its drug Anktiva, causing investors to suffer damages.

Why it matters

This lawsuit highlights the importance of transparency and accurate disclosures from public companies. Investors rely on companies to provide truthful information about their products and financial performance, and allegations of misleading statements can erode trust and lead to significant losses.

The details

According to the lawsuit, ImmunityBio and its executives, including Chairman and CEO Patrick Soon-Shiong, made false and/or misleading statements about the capabilities of Anktiva, the company's lead drug candidate. The lawsuit claims that the defendants' statements about ImmunityBio's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.

  • The class period covers the period from January 19, 2026 to March 24, 2026.
  • The deadline for investors to join the class action lawsuit is May 26, 2026.

The players

ImmunityBio, Inc.

A clinical-stage biotechnology company focused on developing therapies to treat cancer and infectious diseases.

Patrick Soon-Shiong

The Chairman and CEO of ImmunityBio, who is alleged to have materially overstated the capabilities of the company's lead drug candidate, Anktiva.

Rosen Law Firm

A global investor rights law firm that has filed the class action lawsuit on behalf of ImmunityBio investors.

Got photos? Submit your photos here. ›

What they’re saying

“Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.”

— Laurence Rosen, Esq.

“If you wish to join the litigation, go to https://rosenlegal.com/submit-form/?case_id=17455 or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at case@rosenlegal.com.”

— Phillip Kim, Esq.

What’s next

The deadline for investors to join the class action lawsuit is May 26, 2026. A lead plaintiff will be appointed to represent the class in the litigation.

The takeaway

This lawsuit highlights the importance of accurate and transparent disclosures from public companies. Investors rely on companies to provide truthful information, and allegations of misleading statements can lead to significant losses and erode trust in the market.